GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2009

Achaogen Scores $26.6M Five-Year Contract Covering Biothreat Bacterial Strains

  • Achaogen received a $26.6 million contract spanning five years from the NIAID. The money will fund the discovery and development of compounds to combat biothreat strains of Gram-negative bacteria such as Yersinia pestis and Francisella tularensis.

    The NIAID funding will support work to extend the spectrum and efficacy of its current leads and to advance one neoglycoside through Phase I trials.

    Achaogen reports that its neoglycosides, or next-generation aminoglycosides, have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multidrug resistant Gram-negative organisms as well as multidrug resistant Gram-positive bacteria. These include Pseudomonas, Acinetobacter, Enterobacteriaceae, MRSA, and vancomycin-resistant Staphylococcus strains.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »